•
China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research and option deal aimed at advancing treatments for central nervous system (CNS) diseases. According to the agreement, Secarna will utilize its nucleic acid discovery and development platform, LNAplus, to generate and profile antisense oligonucleotide (ASO)…
•
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi in its inaugural funding round, which was exclusively led by Delian Capital. The capital raised will be directed towards enhancing QL Bio’s “one-stop proteomics platform” and advancing the discovery and clinical application of protein biomarkers.…
•
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for its potentially groundbreaking oncolytic virus product, MVR-C5252, which is under development to treat gliomas. This first-in-class product marks a significant step forward in the treatment of brain tumors. Global Context and PrecedenceIn June 2021, Japanese…
•
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands, and Suzhou (China), has released its financial report for the period ending December 31, 2022. The company reported a total revenue of USD 40.659 million, marking an increase of 846.5% year-on-year (YOY). Research and development…
•
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its respiratory syncytial virus (RSV) adult vaccine development program, which includes discontinuing a Phase III trial. This strategic move is a response to the current RSV vaccine landscape and is part of an effort to optimize…
•
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total revenue of RMB 5.982 billion (USD 869.8 million), marking a 15.0% year-on-year (YOY) increase. The company’s performance reflects significant growth, particularly in its tumor treatment sector, which saw a 63.1% increase to RMB 2.306 billion…
•
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib, a Janus kinase 3 (JAK3) inhibitor, is on track for priority review status for the treatment of vitiligo in China. This development highlights the potential fast-track approval process for this novel therapy in addressing the…
•
Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced a partnership agreement with China-based Scivita Medical Technology Co., Ltd. The collaboration pertains to the development of a disposable electronic choledochoscope, although no financial details have been disclosed. Boston Scientific’s Extensive Business Presence in ChinaBoston…
•
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab), a humanized ADCC-enhanced anti-Claudin 18.2 monoclonal antibody (mAb), has received orphan drug designation (ODD) status from the US FDA for the treatment of pancreatic cancer. This follows a previous ODD granted in 2021 for the…
•
China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the Chinese Center for Disease Control and Prevention (CDC). This collaboration aims to enhance various aspects of disease prevention and public health development in China, marking a significant step forward in the nation’s healthcare strategy. Areas…
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its Phase II clinical study (IMM01-02), which investigates the combination of IMM01 with azacitidine for the treatment of naïve chronic myelomonocytic leukemia (CMML). The study has fully enrolled 20 patients, marking a significant milestone in the…
•
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment in the RADIUS-HTN study for its Iberis renal radiofrequency denervation (RDN) system, marking a significant milestone in Bordeaux, France. Objectives and Design of the RADIUS-HTN StudyThe RADIUS-HTN study is designed to assess the performance of…
•
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has entered into a licensing agreement with Taiwan-based Orient EuroPharma Co., Ltd for the immunotherapy drug oregovomab. The agreement grants Orient exclusive commercialization rights to oregovomab in Taiwan, with additional preemptive rights for exclusive sales, marketing,…
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of proceeds from previous subscriptions. The company has decided to redirect HKD 509 million (USD 64.8 million), initially intended for the clinical development and commercialization of proxalutamide, pyrilutamide, and AR-PROTAC GT20029, away from clinical studies for…
•
US pharmaceutical giant Pfizer (NYSE: PFE) has announced a strategic partnership agreement with China’s Health China Research Center (HCRC). This long-term collaboration is aimed at supporting the “Healthy China” initiative, with a focus on several key areas including research into equitable access to basic health services, the scientific and standardized…
•
Biopharmaceutical company Innovent Biologics Inc., (HKG: 1801), has reported revenues of RMB 4.55 billion (USD 660.6 million) for 2022, reflecting a 6.7% year-on-year (YOY) increase. Product revenues specifically reached RMB 4.139 billion (USD 600.9 million), up 3.4% YOY. This growth was driven by increased volumes and new product revenues, despite…
•
A Japanese national and executive at the Chinese division of Tokyo-based Astellas Pharma Inc. (TYO: 4503) has been arrested by China’s state security bureau on suspicion of espionage. The specific details of the alleged charges have not been disclosed to the public. The arrest was initially reported by Japanese media…
•
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its drug candidate, SPH4336. This designation is for the potential treatment of liposarcoma, a rare form of cancer.…
•
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV) with Taiwan-headquartered Rxilient Biotech to develop and commercialize its programmed death-1 (PD-1) inhibitor, Tuoyi (toripalimab), across Southeast Asia. The agreement covers key territories including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.…
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III NATALEE study has achieved its primary endpoint of invasive disease-free survival (iDFS). The study assessed the efficacy of Kisqali (ribociclib) in combination with endocrine therapy (ET) for hormone receptor-positive/human epidermal growth factor receptor 2 negative…